Table 2. Pulmonary function tests in 61 patients with combined pulmonary fibrosis and emphysema
TestPatients tested n
FVC % pred6190±18 (47–125)
FEV1 % pred6180±21 (33–123)
Post-bronchodilator improvement in FEV1 L360.06±0.13 (-0.35–0.3)
FEV1/FVC %6169±13 (30–94)
FEF25–75% % pred5751±26 (15–118)
TLC % pred5688±17 (44–132)
RV % pred5690±32 (35–188)
DLCO % pred5737±16 (10–80)
KCO % pred5746±19 (8–84)
PaO2 at rest (surpine position) kPa618.4±1.9 (4.6–13.3)
PaCO2 at rest (surpine position) kPa614.9±0.7 (3.0–7.3)
Alveolar–arterial PaO2 difference (room air) kPa615.5±2.1 (0.1–11.7)
PaO2 at exercise–PaO2 at rest (surpine position) kPa22-1.5±1.6 (-4.4–1.7)
6-min walking distance m23336±139 (50–548)
Decrease in SpO2 during 6-min walk test %23-8.9±5.7 (-20–0)
  • Data are presented as mean±sd (range), unless otherwise stated. FVC: forced vital capacity; % pred: % predicted; FEV1: forced expiratory volume in 1 s; FEF25–75%: mean forced expiratory flow between 25% and 75% of FVC; TLC: total lung capacity; RV: residual volume; DLCO: diffusing capacity of the lung for carbon monoxide; KCO: transfer coefficient of the lung for carbon monoxide; PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension; SpO2: arterial oxygen saturation measured by pulse oximetry. Reproduced from [4].